1. Structurally diverse diterpenoids and phenanthrene derivatives from the roots of Baliospermumsolanifolium.
- Author
-
Chen J, Li Y, Xu H, Lian M, Wang H, and Zhu D
- Subjects
- Humans, Mice, Animals, Molecular Structure, RAW 264.7 Cells, Cell Proliferation drug effects, Structure-Activity Relationship, Cell Line, Tumor, Dose-Response Relationship, Drug, Molecular Conformation, Lipopolysaccharides pharmacology, Lipopolysaccharides antagonists & inhibitors, Diterpenes chemistry, Diterpenes pharmacology, Diterpenes isolation & purification, Phenanthrenes chemistry, Phenanthrenes pharmacology, Phenanthrenes isolation & purification, Plant Roots chemistry, Antineoplastic Agents, Phytogenic pharmacology, Antineoplastic Agents, Phytogenic chemistry, Antineoplastic Agents, Phytogenic isolation & purification, Drug Screening Assays, Antitumor, Nitric Oxide biosynthesis, Nitric Oxide antagonists & inhibitors
- Abstract
Ten undescribed diterpenoids (1-10) and three undescribed phenanthrene derivatives (11-13), together with seven known compounds, were isolated from the roots of Baliospermum solanifolium. Their structures were determined by a combination of spectroscopic data analysis, electronic circular dichroism calculations and single-crystal X-ray diffraction studies. Compounds 1-7 (baliosperoids A-G) represent the examples of 20-nor-ent-podocarpane class first discovered in nature. In particular, compound 7 possesses a unique 2,3-seco ring system incorporating γ-butanolide moiety. All isolates were assessed for their cytotoxic activities against HT-29, HCT-116, HCT-15, MCF-7, and A549 cell lines as well as their inhibitory effects on lipopolysaccharide-induced NO production in RAW264.7 cells. Compound 1, a 20-nor-ent-podocarpane-type diterpenoid possessing a Δ
1,2 double bond, not only exhibited considerable proliferation inhibition against five human cancer cell lines, with IC50 values ranging from 4.13 to 23.45 μM, but also displayed the most potent inhibitory activity on NO production with IC50 value at the nanomolar level (0.63 ± 0.21 μM)., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF